Basilea Pharmaceutica is one of few biopharmaceutical companies in the world focused on the research, development and commercialization of targeted oncology small molecules and new antibiotics and antifungals.

The Basel-based company, listed since 2004 (SIX:BSLN) has successfully brought to market 2 anti-infective brands: Cresemba® (isavuconazole), for the treatment of invasive fungal infections and Zevtera®, an antibiotic for the treatment of severe hospital bacterial infections.

  • Nominated in 2020